Breaking Finance News

Zacks Investment Research upgraded Medical Transcription Billing Corp (NASDAQ:MTBC) to Hold in a report released today.

Yesterday Medical Transcription Billing Corp (NASDAQ:MTBC) traded 6.38% higher at $1.70. The company’s 50-day moving average is $1.80 and its 200-day moving average is $1.50. The last closing price is up 133.32% from the 200-day moving average, compared to the S&P 500 which has increased 0.03% over the same time. 2,083,942 shares of the stock were exchanged, up from an avg. volume of 1,463,580

Zacks Investment Research has upgraded Medical Transcription Billing Corp (NASDAQ:MTBC) to Hold in a report released on 6/08/2017.

Recent Performance Chart

Medical Transcription Billing Corp (NASDAQ:MTBC)

Medical Transcription Billing Corp has with a one year low of $0.29 and a one year high of $5.44 and has a market capitalization of $0.

General Company Details For Medical Transcription Billing Corp (NASDAQ:MTBC)

Medical Transcription Billing, Corp. is a healthcare information technology company that provides an integrated suite of Web-based solutions, together with related business services, to healthcare providers practicing in ambulatory care settings. The Company's offering, PracticePro, allows healthcare practices with the core software and business services on Software-as-a-Service (SaaS) platform. PracticePro includes practice management software and related tools, which facilitate the day-to-day operation of a medical practice; electronic health records (EHR), which allow its customers to qualify for government incentives; revenue cycle management (RCM) services, which include medical billing, analytics and related services, and mobile Health (mHealth) solutions, including smartphone applications that assist patients and healthcare providers in the provision of healthcare services. The Company offers a clearinghouse service, which allows clients to track claim status.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.